Boston Scientific Co. (NYSE:BSX) EVP Jeffrey B. Mirviss Sells 10,989 Shares

Boston Scientific Co. (NYSE:BSXGet Rating) EVP Jeffrey B. Mirviss sold 10,989 shares of the company’s stock in a transaction on Tuesday, April 19th. The shares were sold at an average price of $45.50, for a total transaction of $499,999.50. Following the completion of the sale, the executive vice president now owns 119,961 shares of the company’s stock, valued at approximately $5,458,225.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

NYSE:BSX traded up $1.38 during mid-day trading on Wednesday, hitting $47.10. The stock had a trading volume of 14,210,806 shares, compared to its average volume of 8,887,248. Boston Scientific Co. has a twelve month low of $37.96 and a twelve month high of $47.50. The stock has a market cap of $67.20 billion, a price-to-earnings ratio of 66.26, a PEG ratio of 2.44 and a beta of 0.83. The company’s 50 day simple moving average is $43.68 and its 200 day simple moving average is $42.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.10 and a current ratio of 1.48.

Boston Scientific (NYSE:BSXGet Rating) last issued its earnings results on Wednesday, February 2nd. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.01. Boston Scientific had a net margin of 8.63% and a return on equity of 14.43%. The business had revenue of $3.13 billion during the quarter, compared to the consensus estimate of $3.11 billion. During the same period last year, the business posted $0.23 EPS. Boston Scientific’s revenue was up 15.5% on a year-over-year basis. As a group, equities analysts forecast that Boston Scientific Co. will post 1.76 earnings per share for the current year.

A number of equities analysts have issued reports on BSX shares. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Thursday, March 24th. Morgan Stanley lowered their target price on Boston Scientific from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, February 3rd. TheStreet cut Boston Scientific from a “b” rating to a “c+” rating in a report on Tuesday, March 8th. Bank of America started coverage on Boston Scientific in a report on Tuesday, March 1st. They set a “buy” rating for the company. Finally, Truist Financial started coverage on Boston Scientific in a report on Wednesday, April 13th. They set a “buy” rating and a $52.00 target price for the company. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $48.90.

A number of large investors have recently modified their holdings of the stock. Transcend Capital Advisors LLC acquired a new stake in Boston Scientific in the 1st quarter valued at about $247,000. Pinnacle Wealth Planning Services Inc. raised its holdings in Boston Scientific by 10.5% in the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 7,947 shares of the medical equipment provider’s stock valued at $352,000 after acquiring an additional 755 shares during the period. Endurance Wealth Management Inc. raised its holdings in Boston Scientific by 400.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 1,250 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 1,000 shares during the period. Xponance Inc. raised its holdings in Boston Scientific by 4.6% in the 1st quarter. Xponance Inc. now owns 96,471 shares of the medical equipment provider’s stock valued at $4,273,000 after acquiring an additional 4,259 shares during the period. Finally, Great Valley Advisor Group Inc. raised its holdings in Boston Scientific by 54.8% in the 1st quarter. Great Valley Advisor Group Inc. now owns 8,185 shares of the medical equipment provider’s stock valued at $362,000 after acquiring an additional 2,896 shares during the period. Institutional investors and hedge funds own 89.75% of the company’s stock.

Boston Scientific Company Profile (Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Recommended Stories

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.